RATIONALE: Colony stimulating factors, such as GM CSF, may increase the number of immune
cells found in bone marrow or peripheral blood. It is not yet known which GM-CSF regimen is
more effective in treating patients with prostate cancer.
PURPOSE: This randomized phase II trial is studying how well GM-CSF works in treating
patients with relapsed prostate cancer.